SCHEMBL5037397

SCHEMBL5037397

N#Cc1ccc(C=O)c(Oc2ccccc2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.57
GAA P10253 1/20 0.57
KMT2A Q03164 1/20 0.57
GRIN1 Q05586 1/20 0.45
GRIN2B Q13224 1/20 0.45
CHEK2 O96017 1/20 0.45
ALDH1A1 P00352 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
AR P10275 3/20 0.43
CSNK1A1 P48729 1/20 0.43
CSNK1D P48730 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TSHR P16473 1/20 0.41
TTR P02766 1/20 0.41
PGR P06401 1/20 0.40
STK10 O94804 1/20 0.39
SLK Q9H2G2 1/20 0.39
CYP19A1 P11511 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18570705 0.85 SCN8A (0.46) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL1764883 0.81 LMNA (0.66) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL5041848 0.81 HPGD (0.60) LMNAGRIN1GRIN2BCHEK2ALDH1A1
SCHEMBL5041847 0.81 HPGD (0.60) LMNAGRIN1GRIN2BCHEK2ALDH1A1
SCHEMBL5837353 0.80 HTR2A (0.57) ALDH1A1ARCYP19A1SLC6A4
SCHEMBL1849155 0.78 LMNA (0.67) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL3932203 0.78 MAOB (0.54) ARERN1
SCHEMBL7337144 0.78 LMNA (0.53) LMNAGAAKMT2AGRIN1GRIN2B
SCHEMBL1398327 0.77 ALDH1A1 (0.58) LMNAALDH1A1CYP1A2CYP2C9AR
SCHEMBL3421698 0.77 AR (0.58) LMNAGAACHEK2ALDH1A1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567498-B1 MANDELIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-01-23 EP disclosed
US-7129238-B2 Mandelic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2006-10-31 US disclosed
EP-1567498-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-08-31 EP disclosed
US-20040122057-A1 Novel mandelic acid derivatives HOFFMANN-LA ROCHE INC. 2004-06-24 US disclosed
WO-2004048335-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-06-10 WO disclosed
US-5863947-A Phenylglycine derivatives useful for treating disorders of the central nervous system ELI LILLY AND COMPANY LIMITED (GB) 1999-01-26 US disclosed
EP-0807621-A1 Derivatives of phenylglycine and use thereof as pharmaceuticals LILLY INDUSTRIES LIMITED (GB) 1997-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122057-A1 Novel mandelic acid derivatives F7, F11, F9 LMNA 1694/4885GAA 1312/4885KMT2A 1963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.